Cambridge, Massachusetts, July 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biopharmaceutical company developing therapeutics that selectively target toxic ...
A massive malvertising campaign is using fake Solana, Luno, and TradingView webpages with malicious JavaScript that instructs browsers to assemble malware directly in memory. The operation has been ...
Cambridge, Massachusetts, July 27, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting ...
William G. Mantyh, M.D. is an Associate Professor with Tenure in Behavioral/Cognitive Neurology at the University of Minnesota, specializing in Alzheimer's disease and related neurodegenerative ...
No ARIA-E observed across all genotypes, including APOE4 homozygotes ARIA-H tracking background rates Early biomarker movement consistent with target engagement 12-month topline results expected in Q1 ...
ProMIS Neurosciences shared positive results for its trial of PMN310, a drug being developed to treat cognitive impairment in people with Alzheimer's disease. The biopharmaceutical company said ...
No ARIA-E observed across all genotypes, including APOE4 homozygotes ARIA-H tracking background rates Early biomarker movement consistent with target engagement 12-month topline results expected in Q1 ...
A decade after the closure of ArcelorMittal left hundreds jobless and a premier industrial asset abandoned, a million-dollar investment described as “Lazarus arising from the dead” ...
JavaScript is disabled in your web browser or browser is too old to support JavaScript. Today almost all web pages contain JavaScript, a scripting programming language that runs on visitor's web ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results